May 22, 2017 4:05pm EDT Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
May 15, 2017 7:00am EDT Tonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update
May 11, 2017 7:00am EDT Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention
May 2, 2017 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
Apr 17, 2017 7:00am EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
Apr 13, 2017 11:30am EDT Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
Apr 11, 2017 7:00am EDT Tonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
Apr 3, 2017 7:00am EDT Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Mar 30, 2017 8:01am EDT Tonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
